Here are five things to know:
1. Alphatec announced degenerative multilevel and L4/L5 spinal segment surgeries were performed with the device.
2. The company hopes the new device helps it compete in the $500 million U.S. lateral market.
3. Alphatec CEO Terry Rich said, "Early feedback from surgeon customers has been very positive regarding the system performance, differentiated feature set and ability to successfully treat even the most complex patient cases with a minimally invasive approach."
4. The device is designed to reduce tissue creep, minimizes psoas retraction time and improve alignment and fusion objectives.
5. The Squadron Retractor is fully compatible with most neuromonitoring platforms allowing safe access through the psoas.
More articles on devices:
Aesculap offers warranty against delamination & visualization — A 1st in spine industry